Incidence and patterns of ALK FISH abnormalities seen in a large unselected series of lung carcinomas

Molecular Cytogenetics

Volumn 5, Issue 1, 2012, Pages

  Dai, Zunyan ^a   Kelly, Joann C ^a   Meloni Ehrig, Aurelia ^b   Slovak, Marilyn L ^a   Boles, Debra ^a   Christacos, Nicole C ^a   Bryke, Christine R ^a   Schonberg, Steven A ^a   Otani Rosa, Jennifer ^a   Pan, Qiulu ^a   Ho, Albert K ^a   Sanders, Heather R ^a   Zhang, Zhong J ^a   Jones, Dan ^a   Mowrey, Philip N ^a  

^a QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

^b AmeriPath ^*  (United States)

Author keywords

Adenocarcinoma; ALK amplification; ALK rearrangement; Crizotinib; EGFR; FISH; KRAS; Non small cell lung cancer

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; EML4 ALK PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; HYBRID PROTEIN; K RAS PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR;

ARTICLE; COHORT ANALYSIS; DNA HYBRIDIZATION; EXON; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE DELETION; GENE FREQUENCY; GENE FUSION; GENE REARRANGEMENT; GENETIC TRANSCRIPTION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG CARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MULTIPLEX POLYMERASE CHAIN REACTION; MUTATIONAL ANALYSIS; PATTERN RECOGNITION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

EID: 84870297371     PISSN: None     EISSN: 17558166     Source Type: Journal    
DOI: 10.1186/1755-8166-5-44     Document Type: Article

References (10)

1. Cancer statistics, 2012. Siegel R, Naishadham D, Jemal A, CA Cancer J Clin 2012 62 10 29 10.3322/caac.20138 22237781
2. The biology and treatment of EML4-ALK non-small cell lung cancer. Sasaki T, Rodig SJ, Chirieac LR, Janne PA, Eur J Cancer 2010 46 1773 1780 10.1016/j.ejca.2010.04.002 20418096
3. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Janne PA, Costa DB, et al. N Engl J Med 2010 363 1693 1703 10.1056/NEJMoa1006448 20979469
4. Clinicoradiologic characteristics of patients with lung adenocarcinoma harboring EML4-ALK fusion oncogene. Fukui T, Yatabe Y, Kobayashi Y, Tomizawa K, Ito S, Hatooka S, Matsuo K, Mitsudomi T, Lung Cancer 2012 77 319 325 10.1016/j.lungcan.2012.03.013 22483782
5. RET, ROS1 and ALK fusions in lung cancer. Takeuchi K, Soda M, Togashi Y, Suzuki R, Sakata S, Hatano S, Asaka R, Hamanaka W, Ninomiya H, Uehara H, et al. Nat Med 2012 18 378 381 10.1038/nm.2658 22327623
6. Exon scanning by reverse transcriptase-polymerase chain reaction for detection of known and novel EML4-ALK fusion variants in non-small cell lung cancer. Sanders HR, Li HR, Bruey JM, Scheerle JA, Meloni-Ehrig AM, Kelly JC, Novick C, Albitar M, Cancer Genet 2011 204 45 52 10.1016/j.cancergencyto.2010. 08.024 21356191
7. Targeting anaplastic lymphoma kinase in lung cancer. Shaw AT, Solomon B, Clin Cancer Res 2011 17 2081 2086 10.1158/1078-0432.CCR-10-1591 21288922
8. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Shaw AT, Yeap BY, Solomon BJ, Riely GJ, Gainor J, Engelman JA, Shapiro GI, Costa DB, Ou SH, Butaney M, et al. Lancet Oncol 2011 12 1004 1012 10.1016/S1470-2045(11)70232-7 21933749
9. ROS1 rearrangements define a unique molecular class of lung cancers. Bergethon K, Shaw AT, Ou SH, Katayama R, Lovly CM, McDonald NT, Massion PP, Siwak-Tapp C, Gonzalez A, Fang R, et al. J Clin Oncol 2012 30 863 870 10.1200/JCO.2011.35.6345 22215748
10. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. Katayama R, Shaw AT, Khan TM, Mino-Kenudson M, Solomon BJ, Halmos B, Jessop NA, Wain JC, Yeo AT, Benes C, et al. Sci Transl Med 2012 4 120ra117